Skip to main content
SpringerLink
Log in

Ovarialkarzinom: alte Probleme und neue Lösungsansätze

  • Chapter
125 Jahre Deutsche Gesellschaft für Gynäkologie und Geburtshilfe

  • 1301 Accesses

Zusammenfassung

Bösartige Tumoren des Eierstocks sind in Deutschland die 5.-häufigste maligne Tumorerkrankung der Frau. Charakteristisch für maligne övarialtumoren ist deren große biologische und morphologische Heterogenität. Die drei Hauptgruppen ovarieller Neoplasien werden in Analogie zu den morphologischen Strukturen nach den jeweiligen Ursprungszellen benannt. Aus dem Zellverband des öberflächenepithels (Zölomepithel) entwickeln sich die epithelialen öva-rialkarzinome. Mit knapp 90% bilden diese die weitaus größte Gruppe der primären övarial-malignome. Sehr viel seltener sind die non-epithelialen övarialmalignome: die malignen Keimzelltumoren mit einer Häufigkeit von 3-5% und die malignen Keimstrang-Stromazell-Tumoren mit einer Häufigkeit von 2-3%. Für die differenzialdiagnostische Abgrenzung bedeutsam sind die metastatischen Tumoren des övars, die auch als sekundäre Malignome bezeichnet werden. Im Zentrum dieser Übersichtsarbeit stehen die epithelialen övarialkarzinome (EÖC).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 14.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Advanced Ovarian Cancer Trials Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomized trials. Brit Med J 303: 884–893

    Google Scholar 

  • Ahem PR, Gore ME (1995) Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 13: 726–732

    Google Scholar 

  • Aida H, Takakuwa K, Nagata H et al. (1998) Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin. Cancer Res 4: 235–240

    PubMed  CAS  Google Scholar 

  • Aletti GD, Gostout BS, Podratz KC et al. (2006) Ovarian cancer surgical respectability: relative impact of disease, patients status and surgeon. Gynecol Oncol 100: 33–37

    Article  PubMed  Google Scholar 

  • Alberts DS, Liu PY, Hannigan EV (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage 111 ovarian cancer N Engl J Med 335: 1950–55

    Article  PubMed  CAS  Google Scholar 

  • American College of Obstetricians and Gynecologists, ACOG (2007) Management of adnexal masses. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); Jul. 14 p. ACOG practice bulletin; no. 83

    Google Scholar 

  • Armstrong DK, Bundy B, Wenzel L et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    Article  PubMed  CAS  Google Scholar 

  • Auersperg N, Wong AS, Choi KC et al. (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22: 255–288

    Article  PubMed  CAS  Google Scholar 

  • Barnes MM, Grizzle WE, Grubbs CJ et al. (2002) Paradigms for primary prevention of ovarian cancer. CA Cancer J 52:216–225

    Article  Google Scholar 

  • Bast RC, Feeney M, Lazarus H et al. (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337

    Article  PubMed  Google Scholar 

  • Baumann K, Wagner U (2008) Präventionsstrategien beim Ovarialkarzinom. Der Gynäkologe 41:513–522

    Article  Google Scholar 

  • Bell J, Brady MF, Young RC et al. (2006) Randomized phase HI trial of three vs six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol oncol 102:432

    Article  PubMed  CAS  Google Scholar 

  • Benedetti Panici P, Maggioni A, Hacker N et al. (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97:560–566

    Article  Google Scholar 

  • Berek JS, Hacker NF, Lagasse LD et al. (1983) Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 61:189–1993

    PubMed  CAS  Google Scholar 

  • Berrio F, Cappocacia R, Coleman MP et al. (2003) Survival of cancer patients in Europe: the EUROCare-3 study. Ann Oncol 14(Suppl 5)v1–v55

    Google Scholar 

  • Berry DA, iversen ES, Gudbjartsson DF et al. (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/ BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20: 2701–12

    Article  PubMed  CAS  Google Scholar 

  • du Bois A, Lück HJ, Bauknecht T et al. (2000) 2nd line Chemotherapie nach Platin- oder Platin-Paclitaxel haltiger Primärtherapie beim Ovarialkarzinom: eine systematische Übersicht der publizierten Daten bis 1998. Geb Frauheilk 60:41–58

    Article  Google Scholar 

  • du Bois A, Lueck HJ, Meier W et al. (2003) A randomized trial of cisplatin/paditaxel versus carboplastin/paditaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1329

    PubMed  CAS  Google Scholar 

  • duBois A, Quinn M, Thigpen T et al. (2005) 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG- OCCC 2004). Ann Oncol 16 (suppl.8) viii7–viii12

    Article  Google Scholar 

  • du Bois A, Rochon J, Lamparter C et al. (2005) Das Qualitätssicherungsprogramm der AGO Organkommission Ovar (QS-OVAR): Versorgungsstruktur und Realität in Deutschland 2001. Zentralbl Gynaekol 127:9–30

    Article  CAS  Google Scholar 

  • duBois A, Reuss A, Harter P et al. (2010) Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase HI multicenter trials J Clin Oncol 28, No 10,1630–1632

    Article  Google Scholar 

  • Bookman MA (2005) Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer 15(Suppl 3) 212–20

    Article  PubMed  Google Scholar 

  • Bookman MA, Brady MF, McGuire WP et al. (2008) Evaluation of new platinum based treatment regimens in advanced ovarian cancer: a Phase 111 trial of Gynecologic Cancer Intergroup. J Clin Oncol 27:1419–1425

    Article  Google Scholar 

  • Brown PO, Palmer C (2009) The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 6(7): el 000114. doi:10.1371 /journal.pmed.1000114

    Google Scholar 

  • Brenner H, Stegmaier C, Ziegler H (2005) Long term survival of cancer patients in Germany achieved by the beginning of the third millennium. Ann Oncol 16:981–986

    Article  PubMed  CAS  Google Scholar 

  • Brewster WR (2005) Temporal trends in ovarian cancer incidence and mortality in Europe. Natl Clin Prac Oncol 2: 286–87

    Article  Google Scholar 

  • Bristow RE, Duska LR, Lambrou NC et al. (2000) A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89:1532–1540

    Article  PubMed  CAS  Google Scholar 

  • Bristow RE, Tomacruz RS, Amstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–59

    Article  PubMed  Google Scholar 

  • van der Burgh ME, van Lent M, Buyse M et al. (1995) Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629–634

    Article  Google Scholar 

  • Burghardt E, Girardi F, Lahousen M et al. (1991) Patterns of pelvic and para-aortic lymph node involvement in ovarian cancer. Gynecol Oncol 40:103–106

    Article  PubMed  CAS  Google Scholar 

  • Carlson KJ, Skates SJ, Singer DE (1994) Screening for ovarian cancer. Ann Intern Med 121:124–132

    PubMed  CAS  Google Scholar 

  • Casagrande JT, Louie EW, Pike MC et al. (1979) Incessant ovulation and ovarian cancer Lancet 2:170

    Article  PubMed  CAS  Google Scholar 

  • Chang J, Fryatt I, Ponder B et al. (1995) Matched control study of familial epithelial ovarian cancer: Patient characteristics, response to chemotherapy and outcome. Ann One 6:80–82

    CAS  Google Scholar 

  • Chen S, Iversen ES, Friebel T et al. (2006) Characterization of BRCA 1 and BRCA2 mutations in a large United States sample. J Cin Oncol 24: 863–871

    Article  CAS  Google Scholar 

  • Colombo N, Parma G, Lapresa MT et al. (2005) A. Role of conservative surgery in ovarian cancer: the European experience, Int J Gynecol Cancer 15 (Suppl 3) 206–211

    Article  PubMed  Google Scholar 

  • Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Interferences regarding pathogenesis. J Natl Cancer Inst 71: 717–721

    PubMed  CAS  Google Scholar 

  • Crum CP, Drapkin R, Miron A et al. (2007) The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19 (1): 3–9

    Article  PubMed  Google Scholar 

  • Decker DG, Fleming TR, Malkasian GD et al. (1982) Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet gynecol 60:481–487

    PubMed  CAS  Google Scholar 

  • Engel J, Hölscher G, Schubert-Fritschle G (2007) Epidemiologie. In: Manual Maligne Ovarialtumoren Tumorzentrum München (Hrsg) B. Schmalfeld Zuckschwerdt Verlag, München 1–12

    Google Scholar 

  • Fishman DA, Cohen L, Blank SV et al. (2005) The role of ultrasound evaluation in the detection of early stage epithelial ovarian cancer. Am J Obstet Gynecol 192:1214–21

    Article  PubMed  Google Scholar 

  • Fathalla MF (1971) Incessant ovulation – a factor in ovarian neoplasia? Lancet 2:163

    Article  PubMed  CAS  Google Scholar 

  • Ferlay J, Bray F, Sanklia R et al. (2004) GOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide, Cancer Base No. 5, Version 2.0. Lyon, France: IARC Press

    Google Scholar 

  • Fleming JS, Beaugie CR, Haviv I et al. (2006) Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypothesis Mol Cell Endocrinol 247:4–21

    Article  PubMed  CAS  Google Scholar 

  • Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104

    PubMed  CAS  Google Scholar 

  • Griffiths CT, Parker LM, Lee S et al. (2002) The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results. Int J Gynecol Cancer 12(4):323–31

    Article  PubMed  CAS  Google Scholar 

  • Harter P, duBois A (2005) The role of surgery in ovarian cancer with special emphasis ion cytoreductive surgery for recurrence. Curr Opin Oncol 17: 505–514

    Article  PubMed  Google Scholar 

  • Harter P, du Bois A, Hahmann M et al. (2006) Surgery in recurrent ovarian cancer – The Arbeitsgemeinschaft Gyna-ekologische Onkologie (AGO) DESKTOP OVAR trial for the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee (AGO OC) and the AGO Ovarian Cancer Study Group (AGO-OVAR). Ann Surg Oncol, online first 10–2006

    Google Scholar 

  • Harter P, Gnauert K, Hils R et al. (2007) Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 17:1238–1244

    Article  PubMed  CAS  Google Scholar 

  • Heintz AP (2006) Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95(Suppl 1): SI 61–92

    Google Scholar 

  • Helleman J (2006) Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118(8):1963–1971

    Article  PubMed  CAS  Google Scholar 

  • Hennessy BT, Markman M (2009) Development of novel agents for ovarian cancer. Update on Cancer Therapeutics 3:119–132 (www.updateoncancer.com)

    Google Scholar 

  • Horner MJ, Ries LAG, Krapcho M et al. (ed) (2009) SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD www.seer.cancer.gov/csrZ1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site.

  • Hreshchyshyn MM, Park RC, Blessing JA et al. (1980) The role of adjuvant therapy in stage I ovarian cancer. Ann J Obstet Gynecol 138:139–145–439

    Google Scholar 

  • International Collaborative Ovarian neoplasm 1 (ICON1) and European Organization for Research and Treatment of Cancer Collaborators. (2003) Adjuvant Chemotherapy in Ovarian Neoplasms (EORTC-ACTION) J Natl Cancer Inst 95:105–112

    Google Scholar 

  • The ICON and AGO Collaborators (2003) Paclitaxel plus platinum based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON 4/AGO2.2 trial. Lancet 361: 2099–2106

    Google Scholar 

  • Jänicke F, Holscher M, Kuhn W et al. (1992) Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70: 2129–2136

    Article  PubMed  Google Scholar 

  • Jemal A, Siegel R, Ward E et al. (2009) Cancer statistics 2009. CA Cancer J Clin 59(4):225–249. Epub 2009 May 27, 56:106–130

    Google Scholar 

  • Kavanagh JJ, Tresukosol D, Edwards C et al. (1995) Carboplatin reinduction after taxanes in patients with platinum-refractory to platinum. J Clin Oncol 13:1584–1588

    PubMed  CAS  Google Scholar 

  • Kiechle M, Meindl A (2006) Das familiäre Mamma-und Ovarialkarzinom. Geburtsh Frauenheilk66:1–4

    Article  Google Scholar 

  • Kindermann G, Maassen V, Kuhn W (1995) Laparoscopic preliminary surgery of ovarian malignancies. Experiences from 127 German gynecologic clinics. Geburtshilfe Frauenheilkd 55(12):687–94

    Article  PubMed  CAS  Google Scholar 

  • Markman M, Hoskins WJ (1992) Responses to salvage therapy in ovarian cancer: a critical need for precise definitions of the treated population. Clin Oncol 10:513–514

    CAS  Google Scholar 

  • Markman M, Bookman M (2000) Second line treatment of ovarian cancer The Oncologist 5: 26–35

    Article  PubMed  CAS  Google Scholar 

  • Markman M, Bundy BN, Alberts DS et al. (2001) Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage 111 ovarian carcinoma: a intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007

    PubMed  CAS  Google Scholar 

  • Markman M, Liu PY, Wilczynski S et al. (2003) Phase HI randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and platinum-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21: 2460–246

    Article  PubMed  CAS  Google Scholar 

  • McGuire WP, Rowinsky EK, Rosenshein NB et al. (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273–279

    PubMed  CAS  Google Scholar 

  • McGuire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334,1–6

    Article  PubMed  CAS  Google Scholar 

  • Meier W, Römisch M, Hepp H (1993) Stellenwert der Rezidivtherapie in der Behandlung des Ovarialkarzinoms. Geburtsh Frauenheilk 53: 30–34

    Article  PubMed  CAS  Google Scholar 

  • Menon U, Gentry-Maharg AG, Hallet R et al. (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).The Lancet Oncology; Vol 10 Issue 4: 327–340

    Article  PubMed  Google Scholar 

  • Meerpohl HG (1984) Chemotherapie fortgeschrittener epithelialer Ovarialkarzinome. Onkologie 7: (Suppl 2) 22–34

    Article  PubMed  Google Scholar 

  • Meerpohl HG, Giese E, Teufel G et al. (1987) Die sekundäre Tumorreduktion bei Patientinnen mit fortgeschrittenem Ovarialkarzinom. Arch Gynecol Obstet 242:411–412

    Article  Google Scholar 

  • Meerpohl HG, Pohl J , Kühnle H et al. (1988) Konsolidierungstherapie bei fortgeschrittenem Ovarialkarzinom und Partiairemission . Berichte Gynäkologie Geburtshilfe, Springer-Verlag 303:125 (abstract)

    Google Scholar 

  • Meerpohl HG, Sauerbrei W, Kühnle H et al. (1997) Randomized study comparing carboplatin/cyclophosphamide and dsplatin/cydophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. Gynecol Oncol 66: 75–84

    Article  PubMed  CAS  Google Scholar 

  • Meerpohl HG (2000) Maligne Ovarialtumoren. In: Baltzer J, Meerpohl HG, Bahnsen J (ed) Praxis der Gynäkologischen Onkologie. Thieme Verlag, 2. Aufl. 233–234

    Google Scholar 

  • Mettler L, Semm K, Shive K (1997) Endoscopic management of adnexal masses. JSLS 1 (2):103–12

    PubMed  CAS  Google Scholar 

  • van Nagell Jr, DePriest PD, Ueland FR et al. (2007) Ovarian Cancer screening with annual transvaginal sonography: findings of 25.000 women screened. Cancer 109:1887–1896

    Article  PubMed  Google Scholar 

  • Naora H (2007) The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev Mol Med9:1–12

    Article  PubMed  Google Scholar 

  • Neijt JP, ten Bokkel Huinink WW, van der Burg ME et al. (1984) Randomized trial comparing two combination chemotherapy regimens (HexaCAF vs. CHAP-5) in advanced ovarian carcinoma. Lancet 2: 594–600

    Article  PubMed  CAS  Google Scholar 

  • Nossov V, Amneus M, Lang J et al. (2008) The early detection of ovarian cancer: from traditional methods to pro-teomics. Can we really do better than serum CA-125? Am J Obstet Gynecol. www.AJOG.org

  • Omura GA, Bundy BN, BerekJS etal. (1986) A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 57:1725–1730

    Article  PubMed  CAS  Google Scholar 

  • Ozols RF, Bundy BN, Greer BE et al. (2003) Phase HI trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage HI ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200

    Article  PubMed  CAS  Google Scholar 

  • Ovarian Cancer Meta- Analysis Project (1991) Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 9:1668–1674

    Google Scholar 

  • Petricoin EF, Ardekani AM, Hitt BA et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. The Lancet 359: 572–577

    Article  CAS  Google Scholar 

  • Pfleiderer A Jr, Kiyan S (1967) The treatment of ovarian carcinoma in the Universitäts-Frauenklinik Tuebingen since 1957 and its results. Med Welt 51 3095–102

    PubMed  Google Scholar 

  • Piccart MJ, Bertelsen K, James K et al. (2000) Randomized intergroup trial of cisplatin-paditaxel versus cisplatin-cydophosphamide in women with advanced epithelial ovarian cancer: three year results. J Natl Cancer Inst 92:699–798

    Article  PubMed  CAS  Google Scholar 

  • Piek JM, Kenemans P, Verheijen RH (2004) Intraperitoneal serous adenocardnoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 191:718–732

    Article  PubMed  Google Scholar 

  • Pothuri B, Leitao MM, Levine DA et al. (2010) Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS ONE; 5(4): el 0358. doi:10.1371/journal.pone.0010358

    Google Scholar 

  • Prömpeler H (2007) Abklärung eines Adnextumors. Gynäkologe 10: 813–832

    Article  Google Scholar 

  • Pujade-Laureine E, Mahner S, Kaern J et al. (2009) A randomized phase HI study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 27 (Suppl) LBA 5509 (abstr.)

    Google Scholar 

  • Qayyum A, Coakley, FV, Westphalen AC et al. (2005) Role of CT and MR imaging in predicting optimal cytoreduc-tion of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 96: 301–306

    Article  PubMed  Google Scholar 

  • Risch HA, McLaughlin JR, Cole DE et al. (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario Canada. J Natl Cancer Inst 98:1694–1706

    Article  PubMed  CAS  Google Scholar 

  • Robert Koch-Institut und Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (2008) Krebs in Deutschland 2003–2004. Häufigkeiten und Trends. 6. Aufl. Berlin

    Google Scholar 

  • Rodrigues-Burford C, Barnes MN, öelschlaeger DK et al. (2001) Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines. Clin Cancer Res 8:202–209

    Google Scholar 

  • Rose PG, Nerenstone S, Brady MF et al. (2004) Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: 2489–2497

    Article  PubMed  CAS  Google Scholar 

  • Rubin C, Benjamin I, Behbakth K et al. (1996) Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J 335:1414–1416

    Google Scholar 

  • Rustin GJ, van der Burgh ME on behalf of MRC and EORTC collaborators(2009) A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA 125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV 05). J Clin Oncol 27:5601–5605

    Google Scholar 

  • Ryerson AB, Eheman C, Burton J et al. (2007) Symptoms, diagnoses, and time to key diagnostic procedures among older US women with ovarian cancer. Obstet Gynecol 109: (5) 1053–62

    Article  PubMed  Google Scholar 

  • Sackett DL, Rosenberg WMC, Gray JAM et al. (1996) Evidence based medicine: what it is and what it isn't. Brit Medical Journal 312: 71–72

    CAS  Google Scholar 

  • Schmutzler R, Schlegelberger B, Meindl A et al. (2003) Beratung, Genetische Testung und Prävention von Frauen mit einer familiären Belastung für das Mamma- und Övarialkarzinom. Interdisziplinäre Empfehlungen des Verbundprojektes »Familiärer Brust- und Eierstockkrebs« der Deutschen Krebshilfe. Med Genet 15:385–395

    Google Scholar 

  • Sehouli J, Mustea A, Konsgen D et al. (2004) Etablierte und experimentelle Prognosefaktoren des Ovarialkarzi-noms. Zentralbl Gynakol 126:315–22

    Article  PubMed  CAS  Google Scholar 

  • Sehouli J, Stengel D, Öskay-Özcelik G et al. (2008) Nonplatinum Topotecan Combinations versus Topotecan alone for recurrent ovarian cancer: results of a phase-Ill study of the North-Eastern German Society of Gynecological Oncology Ovarian cancer study group. J Clin Oncol 26: 3176–82

    Article  PubMed  CAS  Google Scholar 

  • Silverberg SG (1989) Prognostic significance of pathologic features. CurrTop Pathol 78: 85–109

    CAS  Google Scholar 

  • Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19:7–15

    Article  PubMed  CAS  Google Scholar 

  • Singer G, Kurman RJ, Chang HW et al. (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160:1223–1228

    Article  PubMed  CAS  Google Scholar 

  • Spechter H (1965) Cytostatic treatment of inoperable primary gynecologic tumors with a view to subsequent surgical removal of the tumors. Muench Med Wochenschr 107 (25) 1263–1266

    CAS  Google Scholar 

  • Statistisches Bundesamt (2006) Datenreport, www.destatis.de

  • Tangjitgamal S, Manasirivithaya S, Saopaiboon M et al. (2009) Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Data Base of systematic reviews. Issue 2

    Google Scholar 

  • Tavassoli FA, Devilee P (eds) (2003) World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon, IARC Press

    Google Scholar 

  • Timmerman D, Testa AD, Bourne T et al. (2005) Logistic regression model to distinguish between benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group J Clin Oncol 23: 8794–8801

    Article  PubMed  Google Scholar 

  • Tirkkonen M, Johannsson O, Agnarsson BA et al.(1997) Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57:1222–1227

    PubMed  CAS  Google Scholar 

  • Trimbos JB, Vergote I, Vermorken JB et al. (2003) EORTC-ACTION collaborators. European Organization for Research and Treatment and Treatment of Cancer: Adjuvant chemotherapy in Ovarian neoplasm. Impact of adjuvant chemotherapy and surgical staging in early stage ovarian carcinoma. J Natl Cancer Inst 95(2) 113–125

    Article  PubMed  CAS  Google Scholar 

  • van der Velde NM, Mounts MJE, Arts HJG et al. (2009) Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 124:919–923

    Article  PubMed  Google Scholar 

  • Vergote I, DeBrabanter J, Fyles A et al. (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357:176–82

    Article  PubMed  CAS  Google Scholar 

  • Vergote I, Trope CG, Amant F et al. (2008) EORTC-GCG/NCIC-CTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer. Plenary presentation at the 12th Biennial meeting International Gynecologic Cancer Society IGCS, Bangkok, Thailand, October 25–28 (abs.)

    Google Scholar 

  • Wiltshaw E, Kroner T (1976) Phase II study of cis-dichlorodiammineolatinum(ll) (NSC-119875) in advanced aden- ocarcinoma of the ovary. Cancer Treat Rep 60(1)55–6

    PubMed  CAS  Google Scholar 

  • Winter-Roach BA, Kitchenr HC, Dickinson HO (2009) Adjuvant (postsurgery) chemotherapy for early stage epithelial ovarian cancer Cochrane Database of Systematic Reviews 2009, Issue 3

    Google Scholar 

  • Young RC, Chabner BA, Hubbard SP et al. (1978) Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 299:1261–1266

    Article  PubMed  CAS  Google Scholar 

  • Young RC, Walton LA, Ellenberg SS et al. (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021–1027

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Frauenklinik St. Vincentius Kliniken, Karlsruhe, 76137

    Prof. Dr. med. Hans- Gerd Meerpohl

Authors
  1. Prof. Dr. med. Hans- Gerd Meerpohl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Meerpohl, H . (2011). Ovarialkarzinom: alte Probleme und neue Lösungsansätze. In: 125 Jahre Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-15012-8_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-15012-8_23

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-15011-1

  • Online ISBN: 978-3-642-15012-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation